These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38260304)

  • 21. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
    Suryawanshi RK; Taha TY; McCavitt-Malvido M; Silva I; Khalid MM; Syed AM; Chen IP; Saldhi P; Sreekumar B; Montano M; Foresythe K; Tabata T; Kumar GR; Sotomayor-Gonzalez A; Servellita V; Gliwa A; Nguyen J; Kojima N; Arellanor T; Bussanich A; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Wang Y; Ghazarian S; Davis G; Rodriguez D; Doudna J; Spraggon L; Chiu CY; Ott M
    Emerg Microbes Infect; 2023 Dec; 12(2):2270071. PubMed ID: 37869789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study.
    Guo L; Zhang Q; Gu X; Ren L; Huang T; Li Y; Zhang H; Liu Y; Zhong J; Wang X; Chen L; Zhang Y; Li D; Fang M; Xu L; Li H; Wang Z; Li H; Bai T; Liu W; Peng Y; Dong T; Cao B; Wang J
    Lancet Microbe; 2024 Jan; 5(1):e24-e33. PubMed ID: 38048805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.
    Liang Z; Tong J; Sun Z; Liu S; Wu J; Wu X; Li T; Yu Y; Zhang L; Zhao C; Lu Q; Nie J; Huang W; Wang Y
    J Med Virol; 2024 Jan; 96(1):e29314. PubMed ID: 38163276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
    Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
    Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
    Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
    Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
    Sohail MS; Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting.
    Cui T; Su X; Sun J; Liu S; Huang M; Li W; Luo C; Cheng L; Wei R; Song T; Sun X; Luo Q; Li J; Su J; Deng S; Zhao J; Zhao Z; Zhong N; Wang Z
    EBioMedicine; 2024 Jan; 99():104903. PubMed ID: 38064992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.